fingolimod hydrochloride has been researched along with Autoimmune Demyelinating Diseases, Central Nervous System in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| de Chalus, A; Deiva, K; Taveira, M | 1 |
| Alassiri, A; Algahtani, H; Shirah, B | 1 |
| Chow, WN; Colello, RJ; Graf, MR; Graham, RS; Lee, KD; Mathern, BE; Sato-Bigbee, C; Young, HF | 1 |
2 review(s) available for fingolimod hydrochloride and Autoimmune Demyelinating Diseases, Central Nervous System
| Article | Year |
|---|---|
Pediatric onset multiple sclerosis: Future challenge for early diagnosis and treatment.
Topics: Adolescent; Age of Onset; Child; Child, Preschool; Cognition Disorders; Demyelinating Autoimmune Diseases, CNS; Diagnosis, Differential; Early Diagnosis; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Infant; Magnetic Resonance Imaging; Male; Multiple Sclerosis; Natalizumab; Sphingosine 1 Phosphate Receptor Modulators; Symptom Assessment | 2021 |
Tumefactive demyelinating lesions: A comprehensive review.
Topics: Adrenal Cortex Hormones; Brain Neoplasms; Central Nervous System Neoplasms; Demyelinating Autoimmune Diseases, CNS; Deprescriptions; Diagnosis, Differential; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Magnetic Resonance Imaging; Multiple Sclerosis; Natalizumab; Plasma Exchange; Risk Factors | 2017 |
1 other study(ies) available for fingolimod hydrochloride and Autoimmune Demyelinating Diseases, Central Nervous System
| Article | Year |
|---|---|
FTY720 reduces inflammation and promotes functional recovery after spinal cord injury.
Topics: Animals; Autoimmunity; Chemotaxis, Leukocyte; Demyelinating Autoimmune Diseases, CNS; Disease Models, Animal; Fingolimod Hydrochloride; Flow Cytometry; Immunosuppressive Agents; Lymphocyte Activation; Myelitis; Nerve Fibers, Myelinated; Nerve Regeneration; Paralysis; Propylene Glycols; Rats; Rats, Long-Evans; Recovery of Function; Sphingosine; Spinal Cord Injuries; T-Lymphocytes; Treatment Outcome; Urinary Bladder, Neurogenic; Wallerian Degeneration | 2009 |